Biogen SMA drug price Novartis estimates for its treatment far too high U.S. group

Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the val...

More From BioPortfolio on "Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group"